{"id":499358,"date":"2021-05-27T08:04:04","date_gmt":"2021-05-27T12:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/"},"modified":"2021-05-27T08:04:04","modified_gmt":"2021-05-27T12:04:04","slug":"cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/","title":{"rendered":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., May  27, 2021  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc.\u00a0(Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody\u00ae technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3<sup>rd<\/sup> at 2:00 p.m. ET. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Doo88P4BSOYqy7-p5Bk86dnXGxm7EF24vl057lwVgGs-a5BGsJbOQde9dM8y-S8LffHTzsPkxAc8UGeR-VqVbg==\" rel=\"nofollow noopener\" target=\"_blank\">www.cytomx.com<\/a>. An archived replay will be available for 30 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CytomX Therapeutics<\/strong><br \/>\n        <br \/>CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody\u00ae technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.<\/p>\n<p align=\"justify\">Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies. First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probodies, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). For additional information about CytomX Therapeutics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Doo88P4BSOYqy7-p5Bk86aai1vnXUdcjdNiF7kTjXt5g7kq7g3-ui2it2etCAy0RP_TZd724gMycB8RR_KvQpg==\" rel=\"nofollow noopener\" target=\"_blank\">www.cytomx.com<\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0muJGJ7Y0qWp55TimVFYiX6T7VfzXZr2RtZtiD17PYPhpHZZrVwNsxRWkCauTyiEUuqLPdnFlZ3nOd4jJHhBb5VvnHTD3qJXy8E7-slZm1BEeyDJQX9jV8isS_MDXwpX\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6hgeQNJu35PFS2oEu-guBpinscUcGIbyXxDy4eQdu5LXxC_vFAn5THijuBgsJeaQ6bs4hEMJlxyVx1DYpAjeAg==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p align=\"justify\">Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.<\/p>\n<p align=\"justify\">\n        <strong>CytomX Contact:<\/strong><br \/>\n        <br \/>Chau Cheng, PhD MBA<br \/>VP, Investor Relations &amp; Corp. Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JvDuIkSG1Xm_g3BlFCrlFzNvIFUVYVxTXcclfDiIhNWogTK8KxgQDHvPnW4hwjtRP41goSD49Oc-F2cGxHlf2A==\" rel=\"nofollow noopener\" target=\"_blank\">ccheng@cytomx.com<\/a><br \/>Direct: (650) 273-4999<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Stern Investor Relations<br \/>Stephanie Ascher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VLQaw4idKGo39h0DgMEXMGMnaOR7AOcbfGWmN-oDqUqmbDWkMpo6AU-KaBxV_3DADyCzOm8zFkQ8rJ2ZJDdogDkAuInXGDttI1OQfJXG6hFdmRTxwlc0r9h7kYeqQVVR\" rel=\"nofollow noopener\" target=\"_blank\">stephanie.ascher@sternir.com<\/a><br \/>212-362-1200<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2bb17e5b-8226-40f6-a847-d3b3a4372056\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc.\u00a0(Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody\u00ae technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3rd at 2:00 p.m. ET. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. An archived replay will be available for 30 days following the event. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499358","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc.\u00a0(Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody\u00ae technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3rd at 2:00 p.m. ET. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. An archived replay will be available for 30 days following the event. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, &hellip; Continue reading &quot;CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T12:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference\",\"datePublished\":\"2021-05-27T12:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/\"},\"wordCount\":460,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/\",\"name\":\"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\",\"datePublished\":\"2021-05-27T12:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc.\u00a0(Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody\u00ae technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3rd at 2:00 p.m. ET. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. An archived replay will be available for 30 days following the event. About\u00a0CytomX Therapeutics CytomX is a clinical-stage, &hellip; Continue reading \"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-27T12:04:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference","datePublished":"2021-05-27T12:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/"},"wordCount":460,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/","name":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=","datePublished":"2021-05-27T12:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0MTkwMyM0MTk4Njc1IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-jefferies-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499358"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499358\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}